Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Farmers Insurance
Federal Trade Commission
QuintilesIMS
Fish and Richardson
UBS
Queensland Health
Boehringer Ingelheim

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,295,652

« Back to Dashboard

Which drugs does patent 9,295,652 protect, and when does it expire?

Patent 9,295,652 protects DORYX MPC and is included in one NDA.
Summary for Patent: 9,295,652
Title:Controlled release doxycycline
Abstract: The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation.
Inventor(s): Lukas; Stefan (Manningham, AU), Lepore; Angelo (Rostrevor, AU), Mudge; Stuart (Northcote, AU)
Assignee: Mayne Pharma International Pty. Ltd. (Salisbury South, AU)
Application Number:14/521,998
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,295,652
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 9,295,652

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET ➤ Try a Free Trial
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-008 May 20, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,295,652

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,446,057 Controlled release doxycycline ➤ Try a Free Trial
9,511,031 Controlled release doxycycline ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Citi
Julphar
Federal Trade Commission
QuintilesIMS
Deloitte
Chinese Patent Office
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.